2 Biotechs Kyle’s Watching… 1 He’s Trading

Edward Lance lorilla, Identifying the best biotechs to buy— and timing them to near perfection— is one of the fastest ways to grow a trading account.  But it can be really hard to make a living as a buy and hold biotech investor. Even the best minds in the world try and can't.  Which means we have to find an exciting catalyst event and trade the price action.  Most of these companies are tiny and essentially count on one drug. There are several things we want to look at, but most important is what phase the trial is in.  There are 3 main trial phases: Phase 1 - basic safety Phase 2 - real safety, very basic efficacy (a lot fail it) Phase 3 - real efficacy (most fail it) So the higher the phase is, the more expensive the company usually is by that point. If phase 3 is successful, we can see stocks go up 20-30%, even as much as 200-400%.  If a company has good trial results, it's likely that the stock is going a lot higher.  Especially if those results are for an "indication"— it's treating something really important… like cancer, diabetes, or a global pandemic.  Here's a couple of biotech catalysts that Kyle is watching, and may put into action through his Trade with Kyle service.   BioNTech (BNTX) The company is focused on developing and manufacturing immunotherapies As of lately, in a combined effort with Pfizer (PFE), the company has been working on a coronavirus vaccine candidate— BNT162b2 According to analysts, BNT162b2 is leading the race and is one of the most promising drugs out there— in Phase 1 exploratory trial nearly all participants demonstrated a robust immune response If successful, the US government plans to order an initial 100 million doses, worth $1.95 billion, and up to 500 million doses annually thereafter The company is expected to release Phase 2/3 data in October 2020 The stock has been grinding higher lately, slowly inching towards resistance at $100    BiondVax Inc. (BVXV)   An Israeli company working on a flu vaccine candidate   It's lead drug candidate, M-001 is based on a unique technology developed by Ruth Arnon— creator of Copaxone, one of TEVA's leading drugs   M-001 demonstrated remarkable safety and efficacy in small scale Phase 1 and Phase 2 trials   The results were impressive enough that the company has received development grants from both the Israeli government and the EU   Data readout from its large scale Phase 3 trial is due in October 2020— if positive, BVXV will become one of the few players in a virtually unlimited flu market   The stock has hit a wall at $40 and has been sitting under it for almost 3 months now   We can't guarantee that Kyle will trade either of these two names.   However, there is one other biotech that Kyle has unusually high-conviction on.   It's a sub $10 biotech pick that's providing solutions to the pandemic.   It just recently received a government contract.   And it currently has a high short interest.   Kyle thinks it could explode to $30-40 within a relatively short period.   If you want to learn how Kyle is trading it, it's urgent to join his Trade with Kyle service now.   For a limited time, Kyle's slashing the price of this service.   You can get in here at a special quarterly price.   But you have to hurry…   Kyle shuts this down at 11:59 PM ET tomorrow.     Teachable Moment: How To Uncover 🔥 Hot Momo Stocks By Jason Bond of Jason Bond Picks Breaking Down The Markets Using My 5 Global Outlook Indicators By Ben Sturgill of Daily Profit Machine Swing Trade Setting Up in SONN By Jeff Williams of Penny Pro Three Options Plays On My Radar By Jason Bond of Jason Bond Picks RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 Click Here to stop receiving emails from support@ragingbull.com Unsubscribe from all RagingBull emails DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website,application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication.